• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在黑色素瘤中鉴定出的NTRK1突变的功能特征

Functional characterization of NTRK1 mutations identified in melanoma.

作者信息

Miranda Claudia, Mazzoni Mara, Sensi Marialuisa, Pierotti Marco A, Greco Angela

机构信息

Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

出版信息

Genes Chromosomes Cancer. 2014 Oct;53(10):875-80. doi: 10.1002/gcc.22200. Epub 2014 Jun 26.

DOI:10.1002/gcc.22200
PMID:24965840
Abstract

Cutaneous melanoma is the most aggressive form of skin cancer, with a complex and heterogeneous aetiology. Deregulation of the mitogen activated protein kinase cascade is common in melanoma, due to activating mutations in the BRAF and NRAS genes. Genetic studies and high-throughput screening technologies have recently identified several somatic mutations affecting different receptor tyrosine kinase (RTK) genes. For the majority of these, however, the contribution to the complexity of melanoma biology has not been assessed. Among these, two novel missense somatic mutations (M379I and R577G) have recently been identified in the gene encoding the neurotrophic RTK NTRK1. The NTRK1 melanoma-associated point mutations were introduced in a NTRK1 expression plasmid. Functional characterization of mutants was assessed after transient and stable transfection in HeLa and NIH3T3 cells, respectively. We showed that M379I and R577G NTRK1 receptors do not display the kinase as constitutively activated and are functionally indistinguishable from the wild-type NTRK1 receptor. Our results indicate that a causative role for M379I and R577G NTRK1 mutations in melanoma development is highly unlikely. This supports the issue that, in parallel to systematic large scale cancer genome screening, functional studies are required to distinguish between mutations that play a causative role in tumor development and others that may only be passenger changes.

摘要

皮肤黑色素瘤是最具侵袭性的皮肤癌形式,其病因复杂且具有异质性。由于BRAF和NRAS基因的激活突变,丝裂原活化蛋白激酶级联反应失调在黑色素瘤中很常见。遗传研究和高通量筛选技术最近发现了几种影响不同受体酪氨酸激酶(RTK)基因的体细胞突变。然而,对于其中大多数突变,尚未评估其对黑色素瘤生物学复杂性的影响。其中,最近在编码神经营养性RTK NTRK1的基因中发现了两种新的错义体细胞突变(M379I和R577G)。将NTRK1黑色素瘤相关点突变引入NTRK1表达质粒中。分别在HeLa和NIH3T3细胞中进行瞬时和稳定转染后,评估突变体的功能特性。我们发现M379I和R577G NTRK1受体不会表现出激酶组成性激活,并且在功能上与野生型NTRK1受体没有区别。我们的结果表明,M379I和R577G NTRK1突变在黑色素瘤发展中起致病作用的可能性极小。这支持了这样一个观点,即与系统性大规模癌症基因组筛查并行,需要进行功能研究以区分在肿瘤发展中起致病作用的突变和其他可能只是过客变化的突变。

相似文献

1
Functional characterization of NTRK1 mutations identified in melanoma.在黑色素瘤中鉴定出的NTRK1突变的功能特征
Genes Chromosomes Cancer. 2014 Oct;53(10):875-80. doi: 10.1002/gcc.22200. Epub 2014 Jun 26.
2
Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity.
Oncogene. 2002 Nov 28;21(54):8334-9. doi: 10.1038/sj.onc.1206052.
3
Lack of BRAF mutations in uveal melanoma.葡萄膜黑色素瘤中缺乏BRAF突变。
Cancer Res. 2003 Sep 15;63(18):5712-5.
4
Absence of BRAF and NRAS mutations in uveal melanoma.葡萄膜黑色素瘤中BRAF和NRAS突变的缺失。
Cancer Res. 2003 Sep 15;63(18):5761-6.
5
Oncogenic rearrangements of the NTRK1/NGF receptor.神经营养因子受体酪氨酸激酶1(NTRK1)/神经生长因子(NGF)受体的致癌重排
Cancer Lett. 2006 Jan 28;232(1):90-8. doi: 10.1016/j.canlet.2005.07.043. Epub 2005 Oct 20.
6
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.皮肤黑色素瘤亚型显示出不同的BRAF和NRAS突变频率。
Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447.
7
NRAS and BRAF mutation frequency in primary oral mucosal melanoma.口腔黏膜原发性黑色素瘤中 NRAS 和 BRAF 突变频率。
Oncol Rep. 2011 Oct;26(4):783-7. doi: 10.3892/or.2011.1385. Epub 2011 Jul 11.
8
Targeting NRAS in melanoma.针对黑色素瘤中的 NRAS。
Cancer J. 2012 Mar-Apr;18(2):132-6. doi: 10.1097/PPO.0b013e31824ba4df.
9
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.黑色素瘤肿瘤中NRAS和BRAF突变与临床特征的关系:一项基于焦磷酸测序进行突变筛查的研究
Melanoma Res. 2006 Dec;16(6):471-8. doi: 10.1097/01.cmr.0000232300.22032.86.
10
Somatic activation of KIT in distinct subtypes of melanoma.黑色素瘤不同亚型中KIT的体细胞激活。
J Clin Oncol. 2006 Sep 10;24(26):4340-6. doi: 10.1200/JCO.2006.06.2984. Epub 2006 Aug 14.

引用本文的文献

1
Therapy among Different Types of Cancers, Review and Future Perspectives.不同类型癌症的治疗方法:综述与未来展望。
Int J Mol Sci. 2024 Feb 17;25(4):2366. doi: 10.3390/ijms25042366.
2
Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.选择性II型TRK抑制剂克服了xDFG突变介导的对第二代抑制剂塞利替尼和瑞波替尼的获得性耐药。
Acta Pharm Sin B. 2024 Feb;14(2):517-532. doi: 10.1016/j.apsb.2023.11.010. Epub 2023 Nov 8.
3
Multi-cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma.
多队列分析确定体细胞NTRK突变作为皮肤黑色素瘤中免疫检查点抑制剂使用的生物标志物。
Clin Transl Med. 2023 Nov;13(11):e1478. doi: 10.1002/ctm2.1478.
4
Characterization of LTr1 derived from cruciferous vegetables as a novel anti-glioma agent via inhibiting TrkA/PI3K/AKT pathway.十字花科蔬菜衍生的 LTr1 通过抑制 TrkA/PI3K/AKT 通路作为新型抗神经胶质瘤药物的特性研究。
Acta Pharmacol Sin. 2023 Jun;44(6):1262-1276. doi: 10.1038/s41401-022-01033-y. Epub 2022 Dec 8.
5
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.中国 NTRK 基因融合型实体瘤诊断与治疗专家共识。
Thorac Cancer. 2022 Nov;13(21):3084-3097. doi: 10.1111/1759-7714.14644. Epub 2022 Sep 20.
6
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for fusion cancers.用于融合癌的小分子原肌球蛋白受体激酶(TRK)抑制剂的研发。
Acta Pharm Sin B. 2021 Feb;11(2):355-372. doi: 10.1016/j.apsb.2020.05.004. Epub 2020 May 23.
7
Prostatic adenocarcinoma with novel gene fusion: a case report.伴有新型基因融合的前列腺腺癌:一例报告
Am J Clin Exp Urol. 2019 Oct 15;7(5):341-345. eCollection 2019.
8
TRK Inhibitors: Clinical Development of Larotrectinib.TRK抑制剂:拉罗替尼的临床开发
Curr Oncol Rep. 2019 Feb 4;21(2):14. doi: 10.1007/s11912-019-0761-y.
9
NTRK fusion-positive cancers and TRK inhibitor therapy.NTRK 融合阳性癌症和 TRK 抑制剂治疗。
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0.
10
TRKing down an old oncogene in a new era of targeted therapy.在靶向治疗的新时代追踪一个古老的癌基因。
Cancer Discov. 2015 Jan;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765. Epub 2014 Dec 19.